Aralez Pharmaceuticals (ARLZ) Sees Unusually-High Trading Volume

Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) saw unusually-strong trading volume on Friday . Approximately 2,243,878 shares changed hands during trading, an increase of 163% from the previous session’s volume of 853,984 shares.The stock last traded at $1.48 and had previously closed at $1.41.

The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its earnings results on Thursday, November 9th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative return on equity of 118.13% and a negative net margin of 112.89%. The business had revenue of $24.30 million during the quarter, compared to the consensus estimate of $22.87 million. During the same period last year, the company earned ($0.32) earnings per share. The business’s revenue for the quarter was up 78.7% compared to the same quarter last year. research analysts forecast that Aralez Pharmaceuticals Inc. will post -1.54 EPS for the current fiscal year.

In other Aralez Pharmaceuticals news, Director Arthur S. Kirsch bought 50,000 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $73,500.00. Following the completion of the transaction, the director now owns 271,609 shares in the company, valued at $399,265.23. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 6.70% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Ballentine Partners LLC raised its holdings in shares of Aralez Pharmaceuticals by 166.7% in the third quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock valued at $183,000 after acquiring an additional 50,000 shares in the last quarter. Isthmus Partners LLC raised its holdings in shares of Aralez Pharmaceuticals by 0.8% in the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock valued at $208,000 after acquiring an additional 1,285 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Aralez Pharmaceuticals by 0.3% in the first quarter. Goldman Sachs Group Inc. now owns 121,494 shares of the company’s stock valued at $260,000 after acquiring an additional 354 shares in the last quarter. Intrinsic Edge Capital Management LLC bought a new stake in shares of Aralez Pharmaceuticals in the second quarter valued at about $270,000. Finally, Brown Advisory Securities LLC bought a new stake in shares of Aralez Pharmaceuticals in the third quarter valued at about $394,000. Institutional investors and hedge funds own 19.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Aralez Pharmaceuticals (ARLZ) Sees Unusually-High Trading Volume” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/12/17/aralez-pharmaceuticals-arlz-sees-unusually-high-trading-volume.html.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply